YOUR DAILY PEPTIDE BRIEFING / SCIENCE / COMMUNITYNew source checks every six hours
Daily Peptide StackNEWS • RESEARCH • COMMUNITY
THE NEWS STACK / SOURCE NOTE

First Human Administration of Senolytic Immunotherapy to Fight Cellular Aging Announced by Immorta Bio.

A source-backed record from the peptide news monitor, with the original source linked below.

BEFORE YOU READ

This page links to the original record; it is not an independent analysis or clinical recommendation.

← Back to Research Stack
Research StackPR Newswire

First Human Administration of Senolytic Immunotherapy to Fight Cellular Aging Announced by Immorta Bio

Immorta Bio announced the first human administration of SenoMune-0257, described by the company as a nine-amino-acid senolytic immunotherapy. This is a company-issued release; clinical safety and efficacy have not been independently established.

Open original source ↗

Collected Nov 5, 2026. Third-party data may change. Consult the original publication or registry for complete methods, findings and status.